Waltz Health Launches Industry-First Direct-to-Employer Model for Obesity Medications
核心洞察
Waltz Health (搜索) introduces the first direct-to-employer access model for FDA-approved obesity medications, targeting self-insured employers with transparent pricing and clinical safeguards.
The platform launches January 1, 2026, featuring real-time eligibility screening, pharmacy routing, and patient engagement services for weight-loss drugs including Wegovy and Zepbound.
Novo Nordisk and Eli Lilly have agreed to participate in the model, addressing the gap where only one-in-five corporate health plans currently cover obesity medications for weight management.
Waltz Health (搜索), an EVERSANA (搜索) company, has launched the first direct-to-employer (DTE) access model for FDA-approved obesity management medications, marking a significant shift in how employers can provide coverage for weight-loss treatments. The platform, set to launch January 1, 2026, targets self-insured employers with transparent pricing, clinical safeguards, and comprehensive employee support for medications like Novo Nordisk's Wegovy (semaglutide) and Eli Lilly's Zepbound (tirzepatide).
Addressing Coverage Gaps in Obesity Treatment
The new model addresses a critical coverage disparity in corporate health plans. While slightly more than half of corporate health plans cover GLP-1 (搜索) medicines for type 2 diabetes, only one-in-five provide coverage for weight management, according to data from the International Foundation of Employee Benefit Plans (IFEBP). This gap has created significant challenges for employees seeking access to obesity medications, with research suggesting many would consider changing jobs to gain coverage.
"Obesity management medicines are driving a major shift in care expectations, and employers are actively searching for solutions that make coverage both clinically responsible and financially viable," said Mark Thierer, co-founder and CEO of Waltz Health (搜索). "This model equips employers with the structure and visibility they need, while offering employees a seamless experience and a covered benefit they can actually use."
Comprehensive Platform Features
The DTE platform integrates fixed pricing with a fulfillment and support ecosystem that aligns with each employer's existing benefit structure. Key features include real-time eligibility screening, pharmacy routing, prescription adjudication, and ongoing patient engagement services. The system confirms medical appropriateness based on FDA label criteria and routes prescriptions to pharmacies with reliable inventory.
Employees can access treatment through their existing healthcare providers or through a telehealth option integrated into the program. The platform provides continuous digital support including refill tracking and adherence tools, designed to simplify the experience while giving employers transparency and control over costs and clinical oversight.
Industry Partnership and Support
Novo Nordisk has agreed to participate in the model, with Ed Cinca, senior vice president of marketing and patient solutions at Novo Nordisk US, stating: "At Novo Nordisk, we want people who need weight management to have frictionless access to treatment, and know they are getting authentic FDA approved medicine. That's why we are working across the spectrum of healthcare delivery, advocating for a seamless patient experience."
Eli Lilly is also collaborating with Waltz Health (搜索) to expand access to its obesity management medicines. Kevin Hern, senior vice president at Lilly Employer, noted: "Employers continue to tell us they want to better support their employees' health but face real challenges in providing coverage for obesity management medicines. We're excited to collaborate with organizations that share our commitment to removing friction and streamlining options for employers to expand access to obesity management medicines for people who need them."
Market Context and Future Implications
The launch comes as GLP-1 (搜索) agonists and other incretin-based therapies have begun transforming the US medicine supply chain, driven by individuals' willingness to self-pay for access. The direct-to-consumer market for weight-loss therapies has gained significant attention, with pharmaceutical companies launching DTC channels for an expanding range of products.
Chicago-based Waltz Health (搜索), acquired by EVERSANA (搜索) in August for an undisclosed sum, originally launched in 2022 with AI-driven marketplace technologies designed to lower overall drug costs. The company has since expanded its prescription-routing capabilities to serve various sectors, including health plans and employers.
As demand grows for obesity medications and other high-value therapies, the DTE model represents a potential foundation for more responsive and responsible employer-sponsored care, offering a new pathway for employers to provide innovative treatments without compromising financial sustainability or clinical oversight.